ARCA Biopharma jumps after announcing data from Genetic-AF trial presentation
Earlier on Wednesday, ARCA biopharma announced that Gencaro atrial fibrillation clinical data from the GENETIC-AF Phase 2B trial have been selected for presentation at the Heart Failure Society of America, HFSA, 2019 Annual Scientific Meeting being held September 13-16 in Philadelphia. William T. Abraham, MD, FACP, FACC, College of Medicine Distinguished Professor, Division of Cardiovascular Medicine at The Ohio State University Wexner Medical Center, will present the data. "Bucindolol response appears to be greater in heart failure patients with less severe left ventricular dysfunction, a patient population with few therapeutic options for AF prevention or heart failure," commented Dr. Abraham, "These data provide additional support for pharmacogenetic guided therapy with bucindolol for the prevention of atrial fibrillation in patients with heart failure We look forward to confirming these important findings in the upcoming Phase 3 PRECISION-AF trial." Shares of ARCA Biopharma spiked as high as 30% earlier to $7.51 per share after the announcement, but have since moderated gains and are currently up 14% to $6.48 per share in afternoon trading on Wednesday.